Loading...

Deltex Medical Group plc

DEMG.LLSE
Healthcare
Medical - Devices
£0.02
£-0.01(-31.43%)

Deltex Medical Group plc (DEMG.L) Stock Overview

Explore Deltex Medical Group plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.3/100

Key Financials

Market Cap663.6K
P/E Ratio-0.35
EPS (TTM)N/A
ROE-0.42%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.03

DEMG.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Deltex Medical Group plc (DEMG.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.03.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.35 and a market capitalization of 663.6K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for DEMG.LStats details for DEMG.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for DEMG.LAnalyst Recommendations details for DEMG.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers esophageal Doppler Probes that is used to measure a patient's central vascular blood flow and fluid status to measure real time blood velocities within the descending aorta; Loops plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure waveform analysis algorithm used during periods of instability or for periods when the ODM mode is unavailable. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting. Its products are used in Covid-19 critical care; sepsis; major abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.

CEO

Andrew Jonathan Mears

Employees

24

Headquarters

Terminus Road, Chichester

Founded

2001

Frequently Asked Questions

;